Alport syndrome

View All

emerging-therapies-for-alport-syndrome-treatment
Breakthroughs in Alport Syndrome Treatment: A New Era of Hope

Alport syndrome, an inherited disease, predominantly manifests in its X-linked form, constituting around 80% of cases. Without intervention, roughly 90% of affected males face kidney failure by age 40, whereas females typically experience a slower progression to this condition. Many Alport syndrome cases go unnotic...

Find More

pharma-news-for-aslan-iqvia-reata-recordati-eusa
Aslan Pharma – IQVIA collaboration; Reata’s kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA

Aslan Pharmaceuticals enters into a strategic collaboration with IQVIA   ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech, a provider of analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organisation for log...

Find More